Pulse Biosciences Grants Equity Inducement Awards to New Employees

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (NASDAQ: PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment based on its
Nano-Pulse Stimulation (NPS) platform, today announced that the
Compensation Committee of the company’s Board of Directors granted
non-qualified stock options to purchase an aggregate of 121,000 shares
of Pulse Biosciences common stock to seven (7) new employees under Pulse
Biosciences, Inc. 2017 Inducement Equity Incentive Award Plan.

The 2017 plan is used exclusively to grant equity awards to individuals
who were not previously an employee or non-employee director of Pulse
Biosciences as an inducement material to such individual’s entering into
employment with Pulse Biosciences in accordance with Nasdaq Marketplace
Rule 5635(c)(4).

The options have an exercise price of $24.78 per share, which is equal
to the closing price of Pulse Biosciences common stock on December 15,
2017. Each option will vest and become exercisable as to 25% of the
shares on the first anniversary of the recipient’s start date, and will
vest and become exercisable as to the remaining 75% of the shares in 36
equal monthly installments following the first anniversary, subject to
each employee’s continued employment with Pulse Biosciences on these
vesting dates. The options are subject to the terms and conditions of
Pulse Bioscience’s 2017 Employment Inducement Equity Incentive Award
Plan, and the award agreements entered into with each recipient.

About Pulse Biosciences

Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment platform based on Nano-Pulse Stimulation
(NPS), a proprietary high-speed cell signaling technology. NPS is a
non-thermal, precise, focal drug-free tissue treatment technology that
directly affects the cell membrane and intracellular structures to
stimulate unique behaviors in cells. NPS can initiate a cell death
process. That process provides a means for the treatment of tissue cells
with minimal inflammatory response. This has the potential to improve
healing outcomes. This process may also contribute to the replacement of
treated tissue cells with healthy new tissue cells. In cancerous
lesions, NPS has been shown in preclinical models to induce immunogenic
cell death (ICD) exposing the unique antigens of the treated cells to
the immune system, resulting in the generation of cytotoxic T-cells and
the mounting of an adaptive immune response targeted against those
cells. Pulse Biosciences is investigating a variety of applications for
its technology that exploits the technology’s unique biologic effect.
More information is available at www.pulsebiosciences.com.

Contacts

Pulse Biosciences, Inc.
Investors:
Brian Dow
Sr.
Vice President and Chief Financial Officer
IR@pulsebiosciences.com
or
The
Trout Group
Mike Zanoni, 646-378-2924
mzanoni@troutgroup.com
or
Media:
Sam
Brown, Inc.
Christy Curran, 615-414-8668
christycurran@sambrown.com

Endari Update

TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus announced today that Endari™ (L-glutamine oral powder) is
packaged and is being shipped to the distributor. An administrative
matter is causing a minor delay in its release; however, Emmaus is
committed to providing Endari to patients as soon as possible and the
date of availability will be announced in the near term.

Endari is indicated to reduce the acute complications of sickle cell
disease in adult and pediatric patients 5 years of age and older. The
most common adverse reactions occurring in greater than 10 percent of
patients receiving Endari in clinical studies were constipation, nausea,
headache, abdominal pain, cough, pain in the extremities, back pain, and
chest pain. Endari should only be taken under the direction of a
physician. Endari has received Orphan Drug designation in the U.S. and
Orphan Medicinal Product designation in the EU.

Emmaus is actively working with payers to ensure coverage and access for
patients with sickle cell disease.

About Sickle Cell Disease

Sickle Cell Disease is an inherited blood disorder characterized by the
production of an altered form of hemoglobin which polymerizes and
becomes fibrous, causing red blood cells to become rigid and change form
so that they appear sickle shaped instead of soft and rounded. Patients
with Sickle Cell Disease suffer from debilitating episodes of sickle
cell crises, which occur when the rigid, adhesive and inflexible red
blood cells occlude blood vessels. Sickle cell crises cause excruciating
pain as a result of insufficient oxygen being delivered to tissue,
referred to as tissue ischemia, and inflammation. These events may lead
to organ damage, stroke, pulmonary complications, skin ulceration,
infection and a variety of other adverse outcomes. Sickle Cell Disease
is an orphan disease, affecting approximately 100,000 patients in the
U.S. and millions worldwide with significant unmet medical needs.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is engaged in the discovery, development and
commercialization of innovative treatments and therapies for rare
diseases. The company’s research on sickle cell disease was initiated by
Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center. For more
information, please visit www.emmauslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and potential commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. Additional risks and uncertainties are described
in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities
and Exchange Commission, including its Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. Emmaus is providing this information as
of the date of this press release and does not undertake any obligation
to update any forward-looking statements as a result of new information,
future events or otherwise.

Contacts

for Emmaus Life Sciences, Inc.
Lori Teranishi, 510-290-6160
lteranishi@iq360inc.com

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar

Celltrion’s Herzuma® (trastuzumab
biosimilar) receives positive opinion from EMA’s CHMP for early breast
cancer, metastatic breast cancer, and metastatic gastric cancer

INCHEON, South Korea–(BUSINESS WIRE)–#CelltrionCelltrion,
Inc.
(KOSDAQ: 068270) announced today that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) issued a positive opinion recommending that Herzuma®
(trastuzumab biosimilar) be granted marketing authorization in the
European Union (EU) for the treatment of patients with early breast
cancer, metastatic breast cancer, or metastatic gastric cancer whose
tumors have either HER2 overexpression or HER2 gene amplification. The
CHMP’s opinion will now be sent to the European Commission (EC) for
final review.

Herzuma® is a biosimilar to Herceptin®i, a
breast cancer and gastric cancer treatment antibody biologic drug
developed by Genentech and marketed by Roche. Herceptin® is a
blockbuster drug which had worldwide sales of CHF 6.8 billionii
(US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1
billion) was in European sales.

“We welcome the CHMP’s recommendation. By providing more treatment
options, biosimilars open more opportunities for greater affordability
and improve access to wider use of biotherapeutics. Herzuma®
could become a cost-effective alternative to biologics for treatment of
breast cancer and gastric cancer, since biologics, which cost much more
than conventional anticancer drugs, place undue financial burden on
patients and the general healthcare system.” said Woo Sung Kee, Chief
Executive Officer of Celltrion.

About Herzuma®

Herzuma® is an anticancer monoclonal antibody (mAb)
biosimilar used to treat breast cancer and gastric cancer. Similarity of
Herzuma® to the reference product, Herceptin®, was
demonstrated in terms of pharmacokinetic, pharmacodynamics, efficacy and
safety through multiple global clinical trials covering various
indications such as HER2-positive early breast cancer, HER2-positive
metastatic breast cancer, and HER2-positive metastatic gastric cancer.
Celltrion also submitted the Biologics License Application (BLA) to the
US Food and Drug Administration (FDA). In 2017, Celltrion launched
Herzuma® in Korea.

About Celltrion, Inc.

Headquartered in Incheon, Korea, Celltrion is a leading
biopharmaceutical company, specializing in research, development and
manufacture of biosimilar and innovative drugs. Celltrion strives to
provide more affordable biosimilar mAbs to patients who previously had
limited access to advanced therapeutics. Celltrion received FDA and EMA
approval for Inflectra® and Remsima®,
respectively, which is the world’s first mAb biosimilar to receive
approval from a regulatory agency in a developed country. Celltrion also
received EMA approval for Truxima® (CT-P10, a mAb biosimilar
to MabThera®iv (rituximab)) in February 2017. For more
information, visit www.celltrion.com.

i Herceptin® is a registered trademark of
Genentech, Inc.
iiRoche
Financial Report 2016

iiiRoche
Financial Report 2016

iv MabThera® is a
registered trademark of Genentech, Inc.

Contacts

Celltrion, Inc.
Gunhyuk Lee, +82 32 850 5168
Gunhyuk.lee@celltrion.com
or
Heewon
Park, +82 32 850 5356
Heewon.park@celltrion.com

PixarBio Corporation Announces Signed Agreement with Lubrizol’s Division, Particle Sciences, to cGMP Manufacture NR14 for Clinical Trials, a 14 Day Post-Surgical Pain Treatment

SALEM, N.H.–(BUSINESS WIRE)–PixarBio Corporation developers of NeuroRelease™NR14, a
14-day post-surgical pain treatment, announces an agreement between
Particle Sciences (PSI), a Lubrizol Corporation Company, to cGMP
manufacture PixarBio’s NR14 product for clinical trials. In 2018,
PixarBio will be able to apply to the US FDA for fast track approval
through the CDER Breakthrough Therapy designation.

“Although the agreement covers our 14 day treatment, we also have a 7
and 3 day product in our pipeline that are not part of this agreement.
We worked for over 3 years with PSI to put this agreement in place and
look forward to a long term collaboration. I am confident that with the
FDA’s fast track approval we can receive FDA clearance to market NR14 in
late 2019,” said CEO Frank Reynolds.

The NeuroRelease™ Platform: Non-Addictive and Non-opiate Treatment of
Pain

NeuroRelease™ is a morphine replacement, and non-addictive
pain platform for post-surgical pain. First product FDA approval for the
platform will be for a 14-day post-surgical pain treatment and it is
expected in late 2019. The platform can be formulated for acute and
chronic pain treatments.

About PixarBio Corporation
PixarBio is a specialty
pharmaceutical/biotechnology company focused on pre-clinical and
clinical commercial development of novel neurological drug delivery
systems for post-operative pain. PixarBio researches and develops
targeted delivery systems for drugs, devices, or biologics to treat
pain, epilepsy, Parkinson’s disease, and spinal cord injury. Our lead
product platform, NeuroRelease™, has achieved sustained therapeutic
release of non-opiate drugs for post-operative, acute and chronic pain
in pre-clinical models. For more information, visit www.pixarbio.com.

Contacts

PixarBio Corporation
Ken Stromsland
617-913-8884
CIO and
VP, External Communication & Investor Relations
info@pixarbio.com

Pharmaceutical Analytical Testing Services Market Procurement Research – Market Trends and Spend Analysis by SpendEdge

LONDON–(BUSINESS WIRE)–#pharmaceutical–Global procurement intelligence advisory firm, SpendEdge,
has announced the release of their ‘Pharmaceutical
Analytical Testing Services Market Procurement Research

Report
.’ The insights and data in this report provide a
strategic analysis of the supply markets, factors influencing purchasing
decisions, procurement best practices, pricing models, supplier
landscape, and an analysis of the supplier capability matrix for the pharma
and healthcare industry
. This report breaks down the data and
analysis behind the procurement of pharmaceutical analytical testing
services and acts as an all-inclusive guide for making smart purchasing
decisions.


“The demand for pharmaceutical analytical testing services is
driven by the increasing stringency of the regulatory framework, rising
costs of drug development, and the growing focus of pharmaceutical
companies toward the development of drugs for new therapeutic areas,”
says SpendEdge procurement analyst A Kowshik. “The increase in demand
for generics and biologics due to the rising healthcare costs around the
world has further motivated global pharmaceutical companies to increase
their geographical presence,” added Kowshik.

Looking for more insights from this report? Request
a free sample report

SpendEdge sample reports are free of charge and provide insights that
focus on cost-saving aspects of procurement and optimization of category
spend.

Procurement analysts at SpendEdge highlight the following top three
market trends that are contributing to the growth of the Global
Pharmaceutical Analytical Testing Services Market:

  • The rising demand for analytical testing services from nutraceuticals
    industry.
  • The increase in technological advancements in analytical testing
    equipment.
  • Increasing adoption of FTE-based contracts.

This report is available at USD 1000 discount for a limited time only:
View
the report snapshot before purchasing

The rising demand for analytical testing services from nutraceuticals
industry:

The increase in regulations for nutraceutical manufacturing companies by
regulatory bodies such as US FDA has led to the rise in demand for
pharmaceutical analytical testing services. The regulatory authorities
demand the nutraceutical manufacturers to get their raw materials tested
to ensure the quality and to conduct release testing for their products.
This has led to the emergence of nutraceuticals industry as an active
consumer of these services. Moreover, it helps the buyers to avoid
implications for non-compliance and to meet the regulatory requirements.

The increase in technological advancements in analytical testing
equipment:

Due to the increase in pressure from the buyers to reduce testing time
for the drug ingredients the suppliers prefer developing and using
advanced equipment for drug testing. The adoption of technology
increases the accuracy and reliability of different analytical
techniques. Also, this eliminates the need for performing multiple
trials of the same test, due to the high accuracy of test results.

Increasing adoption of FTE-based contracts:

FTE-based contracts enable both the supplier and the client to manage
the resources relevant to the project, compared with a conventional
contract in which the supplier is solely responsible for managing the
resources. Employing a dedicated team for the project enables the buyers
to accommodate changes in the project related to the scope of work,
priorities, and project timelines. Moreover, an FTE agreement ensures
high efficiency and quick turnaround time.

Get unlimited access to all our reports. Our Insights platform
provides ready-to-use procurement research reports, latest supplier
news, innovation landscape, markets insights, supplier tracking, and
much more at the click of a button.
Start
your 14-day trial now
.

We also customize
reports
to meet clients’ requirements.

Browse Related Reports:

Global
Drug Substance Manufacturing Category – Procurement Market Intelligence
Report

Global
Pharmaceutical Drug Development Services Category – Procurement Market
Intelligence Report

Global
Pharmaceutical Formulations Category – Procurement Market Intelligence
Report

Global
Pharmaceutical Excipients Category – Procurement Market Intelligence
Report

About SpendEdge

SpendEdge shares your passion for driving sourcing and procurement
excellence. We are a preferred procurement market intelligence partner
for Fortune 500 firms and other leading companies across numerous
industries. Our strength lies in delivering robust, real-time
procurement market intelligence that helps sourcing and procurement
professionals make informed decisions. These innovative procurement
solutions help enterprises transform structural capabilities, improve
execution efficiency, and fast-track time to savings.

Contacts

SpendEdge
Shilpa Balakrishnan
US: +1 (844) 746-0600
hello@spendedge.com

Swine and Avian Influenza Drug Development Pipeline Review 2017 – 63 products in development for this indication by 47 companies and 6 academic institutions – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Swine
and Avian Influenza Drug Development Pipeline Review, 2017”

report has been added to Research and Markets’ offering.

This report provides an overview of the Swine and Avian Influenza
pipeline landscape. The report provides comprehensive information on the
therapeutics under development and key players involved in therapeutic
development for influenza A virus, subtypes H5N1 and H1N1, and features
dormant and discontinued projects. Symptoms of influenza include fever
and cough, fatigue, acute respiratory distress, shortness of breath,
abdominal pain and diarrhea.

H5N1 is a type of influenza virus that causes a highly infectious,
severe respiratory disease in birds called avian influenza. This virus
can spread to humans. There are a total of 63 products in development
for this indication, by 47 companies and six academic institutions. Key
companies operating in this pipeline space include Gemmus Pharma,
Aphios, Fides Pharma, Inovio Pharmaceuticals, Microbiotix,
NanoViricides, Shionogi, the University of Wisconsin Madison and Tria
Bioscience.

H1N1 Infection also called as swine flu is a new kind of flu in humans.
It’s caused by the contagious H1N1 influenza virus. There are a total of
99 products in development for this indication, by 67 companies and 14
academic institutions. Key companies operating in this pipeline space
include Johnson & Johnson, and the University of Sherbrooke.

In both types of influenza, the most common molecular target being
studied is hemagglutinin, by a considerable margin. However, a number of
both human and viral proteins are also under active development.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage
    of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within
    this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to
    have happened in this disease area?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/99vnkr/swine_and_avian?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Drug
Discovery
, Infectious
Diseases Drugs
, Animal
Healthcare/Veterinary

Cancer Supportive Care Drug Development Pipeline Review 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Cancer
Supportive Care Drug Development Pipeline Review, 2017”
report
has been added to Research and Markets’ offering.

There are a total of 24 products in development for this indication, by
18 companies and four academic institutions.

Bone metastasis occurs when cancer cells spread from their original site
to a bone. Signs and symptoms of bone metastasis include bone pain,
broken bones, urinary incontinence, bowel incontinence and weakness in
the legs. There are a total of 32 products in development for this
indication, by 22 companies and four academic institutions. Key
companies operating in this pipeline space include MetCure Therapeutics,
Applied Integrin Sciences, Eli Lilly, and Tel Aviv University.

Cancer pain can be defined as a complex sensation that reflects both
damage to the body and the body’s response to the damage. Pain may arise
due to tumor compressing or infiltrating tissue, from treatments and
diagnostic procedures, or from skin, nerve and other changes caused by
either the body’s immune response or hormones released by the tumor.
There are a total of 52 products in development for this indication, by
40 companies and four academic institutions. Key companies operating in
this pipeline space include Komipharm, Trillium Therapeutics,
AstraZeneca, Insys Therapeutics, Klaria Pharma and Pharmaleads.

The majority of products in cancer anorexia-cachexia syndrome target the
growth hormone secretagogue receptor type 1, although there are a range
of other molecular targets in development. Within bone metastasis, the
most common molecular targets are the tumor necrosis factor ligand
superfamily member 11, and the hepatocyte growth factor receptor, along
with a range of others. Finally, within cancer pain, neurotransmitters
such as the mu type opioid receptor, and a range of ion channels, are
the most common type of target, reflecting the pain treatment landscape
in general.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage
    of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within
    this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to
    have happened in this disease area?

Key Topics Covered:

1 List of Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/4k86p3/cancer_supportive?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Drug
Discovery
, Oncology
Drugs

United States Cloderm Promotional Activity Report 2016-2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Cloderm
2016 U.S. Promotional Report”
report has been added to Research
and Markets’
offering.

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Cloderm through personal promotion
    in 2016 and how does this compare to its peer set in the Dermatosis
    markets?
  • What promotional mix was leveraged (e.g., sales rep detailing,
    physician education, and paid speaking) and what was the median spend
    on each type of activity?
  • How does Promius’s depth of coverage vary within key specialties
    (e.g., Dermatology) and how does this compare to its peers and the
    overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Cloderm throughout
    the year (e.g., monthly, quarterly, annually)?
  • Who were the most detailed prescribers and top paid speakers for
    Cloderm in 2016?

Data Sources and Methodology:

  • We leverage company-reported financial transaction data disclosed
    through CMS Open Payments. This data set captures all transfers of
    value (e.g., speaking fees, consulting fees, travel, education, and
    meals) made on behalf of a drug or device manufacturer to a physician.
    Currently, 42 months of longitudinal data is available – covering
    payments to more than 900,000 U.S. healthcare professionals.
  • Over 800 paid interactions across 500 physicians made on behalf of
    Cloderm were carefully examined to support our analysis. In addition,
    interaction data from 4 peer products (e.g. Locoid, Neo-Synalar,
    Novacort, and Synalar) was leveraged to provide benchmarking and
    market insights.

For more information about this report visit https://www.researchandmarkets.com/research/nzbmgn/united_states?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Dermatological
Drugs
, Psoriasis
Drugs

United States Arzerra Promotional Activity Report 2016-2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Arzerra
2016 U.S Promotional Report”
report has been added to Research
and Markets’
offering.

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Arzerra through personal promotion
    in 2016 and how does this compare to its peer set in the Chronic
    Lymphocytic Leukemia markets?
  • What promotional mix was leveraged (e.g., sales rep detailing,
    physician education, and paid speaking) and what was the median spend
    on each type of activity?
  • How does Novartis’s depth of coverage vary within key specialties
    (e.g., Neurology, Hematology, Hematology/Oncology, Internal Medicine,
    and Medical Oncology) and how does this compare to its peers and the
    overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Arzerra throughout
    the year (e.g., monthly, quarterly, annually)?
  • Who were the most detailed prescribers and top paid speakers for
    Arzerra in 2016?

Data Sources and Methodology:

  • We leverage company-reported financial transaction data disclosed
    through CMS Open Payments. This data set captures all transfers of
    value (e.g., speaking fees, consulting fees, travel, education, and
    meals) made on behalf of a drug or device manufacturer to a physician.
    Currently, 42 months of longitudinal data is available – covering
    payments to more than 900,000 U.S. healthcare professionals.
  • Over 200 paid interactions across 200 physicians made on behalf of
    Arzerra were carefully examined to support our analysis. In addition,
    interaction data from 6 peer products (e.g. Gazyva, Imbruvica,
    Rituxan, Treanda, Venclexta, and Zydelig ) was leveraged to provide
    benchmarking and market insights.

For more information about this report visit https://www.researchandmarkets.com/research/gbjt88/united_states?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Leukemia
Drugs

Breo 2016-2017 U.S. Promotional Report – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Breo
2016 U.S. Promotional Report”
report has been added to Research
and Markets’
offering.

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Breo through personal promotion in
    2016 and how does this compare to its peer set in the Asthma and
    Chronic Obstructive Pulmonary Disease markets?
  • What promotional mix was leveraged (e.g., sales rep detailing,
    physician education, and paid speaking) and what was the median spend
    on each type of activity?
  • How does GSK’s depth of coverage vary within key specialties (e.g.,
    Family Medicine, Internal Medicine, Pulmonology, and
    Allergy/Immunology) and how does this compare to its peers and the
    overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Breo throughout the
    year (e.g., monthly, quarterly, annually)?
  • Who were the most detailed prescribers and top paid speakers for Breo
    in 2016?

Data Sources and Methodology:

  • We leverage company-reported financial transaction data disclosed
    through CMS Open Payments. This data set captures all transfers of
    value (e.g., speaking fees, consulting fees, travel, education, and
    meals) made on behalf of a drug or device manufacturer to a physician.
    Currently, 42 months of longitudinal data is available – covering
    payments to more than 900,000 U.S. healthcare professionals.
  • Over 129,000 paid interactions across 38,800 physicians made on behalf
    of Breo were carefully examined to support our analysis. In addition,
    interaction data from 19 peer products (e.g., Advair, Aerospan, Anoro,
    Arnuity, Asmanex, Brovana, Cinqair, Daliresp, Dulera, Flovent,
    Incruse, Nucala, Perforomist, ProAir, Qvar, Spiriva, Stiolto,
    Symbicort, and Xolair) was leveraged to provide benchmarking and
    market insights.

For more information about this report visit https://www.researchandmarkets.com/research/84zrvs/breo_20162017_u?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs
, Asthma
Drugs